120 related articles for article (PubMed ID: 23897179)
1. The pharmacokinetics of recombinant human erythropoietin in Balkan endemic nephropathy patients.
Ležaić V; Petković N; Marić I; Miljković B; Vučićević K; Simić-Ogrizović S; Pejovic V; Djukanović L
Nefrologia; 2013; 33(4):478-85. PubMed ID: 23897179
[TBL] [Abstract][Full Text] [Related]
2. [Higher dose of erythropoietin for anemia correction in balkan endemic nephropathy patients].
Lukić L; Mitrović D; Kovačević S; Stanišić M; Pelemiš S
Srp Arh Celok Lek; 2012; 140(7-8):456-61. PubMed ID: 23092030
[TBL] [Abstract][Full Text] [Related]
3. Hemodialysis treatment in patients with Balkan endemic nephropathy: an epidemiological study.
Cukuranovic R; Jovanovic I; Miljkovic S; Stefanovic N; Vlajkovic S; Prokopovic M; Stefanovic V
Ren Fail; 2007; 29(7):805-10. PubMed ID: 17994447
[TBL] [Abstract][Full Text] [Related]
4. [Balkan endemic nephropathy in Bosnia and Herzegovina--renal registry report].
Mesić E; Lukić L; Dolenec L; Petković N; Stipancić Z; Resić H; Trnacević S; Halilbasić A
Med Arh; 2006; 60(4):240-2. PubMed ID: 16761518
[TBL] [Abstract][Full Text] [Related]
5. Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: a parallel, randomized, double blind study.
Pérez-Oliva JF; Casanova-González M; García-García I; Porrero-Martín PJ; Valenzuela-Silva CM; Hernández-Montero T; Lagarde-Ampudia M; Casanova-Kutsareva Y; Avila-Albuerne Y; Vargas-Batista A; Bobillo-López H; Herrera-Valdés R; López-Saura PA;
BMC Nephrol; 2005 May; 6():5. PubMed ID: 15910687
[TBL] [Abstract][Full Text] [Related]
6. Surprising good antioxidant status in patients with Balkan Endemic Nephropathy on hemodialysis undergoing vitamin C therapy. A pilot study.
Gluhovschi C; Modilcă M; Margineanu M; Gluhovschi G; Velciov S; Petrica L; Barzuca E; Gădălean F; Ivascu S; Kaycsa A; Ghiocel C
Rom J Intern Med; 2014; 52(3):158-61. PubMed ID: 25509559
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of darbepoetin alpha in hemodialysis patients resistant to human recombinant erythropoietin (rHuEpo).
Hejaili F
Saudi J Kidney Dis Transpl; 2009 Jul; 20(4):590-5. PubMed ID: 19587498
[TBL] [Abstract][Full Text] [Related]
8. Differences in Risk Factors and Prevalence of Vascular Calcification between Pre-Dialysis and Hemodialysis Balkan Nephropathy Patients.
Petković N; Ristić S; Marinković J; Marić R; Kovačević M; Djukanović L
Medicina (Kaunas); 2018 Mar; 54(1):. PubMed ID: 30344235
[No Abstract] [Full Text] [Related]
9. Detection of renal dysfunctions in family members of patients with Balkan endemic nephropathy.
Arsenović A; Bukvić D; Trbojević S; Marić I; Djukanović L
Am J Nephrol; 2005; 25(1):50-4. PubMed ID: 15731549
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers of oxidative damage and antioxidant enzyme activities in pre-dialysis Balkan endemic nephropathy patients.
Pavlović D; Savić-Radojević A; Plješa-Ercegovac M; Radić T; Ristić S; Ćorić V; Matić M; Simić T; Djukanović L
Int Urol Nephrol; 2016 Feb; 48(2):257-63. PubMed ID: 26725075
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of criteria for the diagnosis of Balkan endemic nephropathy.
Djukanović L; Marić I; Marinković J; Ignjatović S; Bukvić D
Ren Fail; 2007; 29(5):607-14. PubMed ID: 17654325
[TBL] [Abstract][Full Text] [Related]
12. [Human recombinant erythropoietin (rH-EPO) in chronic hemodialysis patients].
Jalil R; Vaccarezza A; Jara A; Lira P; Vial S; Serrano V
Rev Med Chil; 1990 Jun; 118(6):629-34. PubMed ID: 1775783
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic and pharmacodynamic studies on recombinant human erythropoietin.
Salmonson T
Scand J Urol Nephrol Suppl; 1990; 129():1-66. PubMed ID: 2255869
[TBL] [Abstract][Full Text] [Related]
14. In vivo 125I-erythropoietin pharmacokinetics are unchanged after anesthesia, nephrectomy and hepatectomy in sheep.
Widness JA; Veng-Pedersen P; Schmidt RL; Lowe LS; Kisthard JA; Peters C
J Pharmacol Exp Ther; 1996 Dec; 279(3):1205-10. PubMed ID: 8968342
[TBL] [Abstract][Full Text] [Related]
15. Comparison of kidney size between patients with Balkan endemic nephropathy and other kidney diseases.
Lezaić V; Marić I; Jovanović D; Radović M; Kovacević Z; Bukvić D; Pavlović S; Matić M; Ajdacić M; Djukanović L
Kidney Blood Press Res; 2008; 31(5):307-12. PubMed ID: 18781078
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and distribution of recombinant erythropoietin in rats.
Kinoshita H; Ohishi N; Kato M; Tokura S; Okazaki A
Arzneimittelforschung; 1992 Feb; 42(2):174-8. PubMed ID: 1610430
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of upper urinary tract tumors in the region of Balkan nephropathy with those of other regions of Yugoslavia].
Djokic M; Hadzi-Djokic J; Nikolic J; Dragicevic D; Radivojevic D
Prog Urol; 1999 Feb; 9(1):61-8. PubMed ID: 10212954
[TBL] [Abstract][Full Text] [Related]
18. Transforming growth factor-beta 1 in Balkan endemic nephropathy.
Dukanović L; Lezaić V; Miljković D; Momcilović M; Bukvić D; Marić I; Miljković Z; Marinković J; Mostarica-Stojković M
Nephron Clin Pract; 2009; 111(2):c127-32. PubMed ID: 19147994
[TBL] [Abstract][Full Text] [Related]
19. Higher apoptotic cell rate in Balkan endemic nephropathy--stereologic analysis.
Belicza M; Dzombeta T; Stanić G; Tomić K; Lenicek T; Perić-Balja M; Vukelić M; Jakovina T; Jakovina K; Kruslin B
Acta Clin Croat; 2011 Mar; 50(1):45-50. PubMed ID: 22034783
[TBL] [Abstract][Full Text] [Related]
20. Familial versus environmental factors in Balkan endemic nephropathy in Mehedinti county, Romania, by means of albuminuria and tubular biomarkers: preliminary study.
Gluhovschi G; Modilca M; Velciov S; Gluhovschi C; Petrica L; Vernic C; Kaycsa A
Ren Fail; 2015 Mar; 37(2):219-24. PubMed ID: 25394278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
